Manulife (Manufacturers Life Insurance)
RXRX icon

Manulife (Manufacturers Life Insurance)’s Recursion Pharmaceuticals RXRX Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$675K Buy
219,998
+15,049
+7% +$58.2K ﹤0.01% 2019
2025
Q4 		$838K Buy
204,949
+18,414
+10% +$91.2K ﹤0.01% 1938
2025
Q3 		$910K Buy
186,535
+3,945
+2% +$20.7K ﹤0.01% 1901
2025
Q2 		$924K Buy
182,590
+45,106
+33% +$222K ﹤0.01% 1856
2025
Q1 		$727K Buy
137,484
+12,770
+10% +$93.1K ﹤0.01% 1955
2024
Q4 		$843K Buy
124,714
+60
+0% +$403 ﹤0.01% 1983
2024
Q3 		$821K Buy
124,654
+13,041
+12% +$93.5K ﹤0.01% 2021
2024
Q2 		$837K Buy
111,613
+27,440
+33% +$239K ﹤0.01% 1944
2024
Q1 		$839K Buy
84,173
+12,002
+17% +$134K ﹤0.01% 1946
2023
Q4 		$712K Sell
72,171
-2,556
-3% -$18.2K ﹤0.01% 2002
2023
Q3 		$572K Buy
74,727
+17,996
+32% +$180K ﹤0.01% 2067
2023
Q2 		$424K Buy
56,731
+560
+1% +$3.92K ﹤0.01% 2140
2023
Q1 		$375K Buy
56,171
+393
+0.7% +$3.12K ﹤0.01% 2185
2022
Q4 		$430K Buy
55,778
+1,458
+3% +$14.3K ﹤0.01% 2084
2022
Q3 		$578K Sell
54,320
-1,074
-2% -$10.9K ﹤0.01% 1883
2022
Q2 		$451K Sell
55,394
-29,566
-35% -$198K ﹤0.01% 2121
2022
Q1 		$607K Buy
84,960
+26,943
+46% +$286K ﹤0.01% 2072
2021
Q4 		$1K Buy
58,017
+41,107
+243% +$773K ﹤0.01% 1822
2021
Q3 		$389K Buy
16,910
+2,670
+19% +$75.7K ﹤0.01% 2472
2021
Q2 		$520K Buy
+14,240
New +$421K ﹤0.01% 2400

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s RXRX Position: Q1 2026 in Review

Manulife (Manufacturers Life Insurance) increased its Recursion Pharmaceuticals (RXRX) stake by 7.3% in Q1 2026, buying an estimated $58.2K and bringing the position to 219,998 shares worth $675K. The position accounts for ﹤0.01% of the portfolio, ranked #2019.

Manulife (Manufacturers Life Insurance) first reported a position in RXRX in Q2 2021 and has held it in 20 quarters since. The position peaked at $924K in Q2 2025. 335 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Manulife (Manufacturers Life Insurance) held 219,998 shares of Recursion Pharmaceuticals worth $675K as of Q1 2026.
  • Manulife (Manufacturers Life Insurance) bought 15,049 Recursion Pharmaceuticals shares in Q1 2026, an estimated $58.2K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q1 2026, its #2019 holding.
  • Manulife (Manufacturers Life Insurance) first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • Manulife (Manufacturers Life Insurance)'s Recursion Pharmaceuticals position peaked at $924K in Q2 2025.
  • 335 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2026, filed 15 May 2026.